A5061885517- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Acute Lymphoblastic Leukemia research
- Rheumatoid Arthritis Research and Therapies
- Inflammasome and immune disorders
- Ocular Diseases and Behçet’s Syndrome
- Spondyloarthritis Studies and Treatments
- Kawasaki Disease and Coronary Complications
- Child and Adolescent Health
- COVID-19 Clinical Research Studies
- Psoriasis: Treatment and Pathogenesis
- Systemic Lupus Erythematosus Research
- Childhood Cancer Survivors' Quality of Life
- Medical and Biological Sciences
- Immunodeficiency and Autoimmune Disorders
- Human Health and Disease
- Cardiovascular Issues in Pregnancy
- Autoimmune and Inflammatory Disorders
- Osteomyelitis and Bone Disorders Research
- Medicinal plant effects and applications
- Congenital Anomalies and Fetal Surgery
- Congenital gastrointestinal and neural anomalies
- Cardiovascular Conditions and Treatments
- Dermatological and COVID-19 studies
- COVID-19 Impact on Reproduction
Sechenov University
2016-2025
City Clinical Hospital
2023
Russian Children's Clinical Hospital
2019-2021
Istituto Giannina Gaslini
2020
Moscow State University
2020
Ministry of Health of the Russian Federation
2020
Cincinnati Children's Hospital Medical Center
2018
Sydney Children's Hospital
2018
University of Cincinnati
2018
Don State Technical University
2018
Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic (JPsA) are currently limited. This trial aimed to demonstrate the efficacy safety of secukinumab active ERA JPsA inadequate response conventional therapy.In this randomised, double-blind, placebo-controlled, treatment-withdrawal, phase 3 trial, biologic-naïve (aged 2 <18 years) disease were treated open-label subcutaneous (75/150 mg <50/≥50 kg) treatment period (TP) 1 up week 12, idiopathic (JIA)...
Psoriatic arthritis is a chronic inflammatory disease of the peripheral joints, spinal joints and entheses, occurring in 10–25% patients with psoriasis. Juvenile psoriatic classified as subtype juvenile idiopathic arthritis. Treatment challenging. One main difficulties that drugs used adult have restrictions for use pediatric practice, which limits available therapeutic options. There are few studies assessing effectiveness safety secakinumab therapy practice. Objective . To evaluate...
Abstract Background Even though the incidence of Multisystem Inflammatory Syndrome in children (MIS-C) is decreasing cases are still reported across world. Studying consequences MIS-C enhances our understanding disease’s prognosis. The objective this study was to assess short- and medium-term clinical outcomes MIS-C. Methods Prospective observational cohort at Municipal Children’s Hospital Morozovskaya, Moscow, Russia. All meeting Royal College Paediatrics Child Health (RCPCH), Centers for...
The Ministry of Health the Russian Federation jointly with professional association and experts in field pediatrics, infectious diseases resuscitation has revised guidelines “Clinical Features Management Disease Caused by New Coronaviral Infection (COVID-19) Children” order to provide child population effective medical care during pandemic new coronaviral infection. practical experience specialists from various countries was considered development this document. Special attention should be...
<h3>Background</h3> Analysis of the incidence rheumatic diseases in children can help to evaluate real needs treatment provision and improve medical service. <h3>Objectives</h3> To analyse prevalence, structure morbidity, therapy pathology Central Federal District Russian Federation. <h3>Methods</h3> Statistical, sociological methods content analysis were used. The study included generalised information on 3940 patients aged 1-17 years with various living 13 regions data is provided by main...
Remission is the primary objective of treating juvenile idiopathic arthritis (JIA). It still debatable whether early intensive treatment superior in terms earlier achievement remission. The aim this study was to evaluate effectiveness etanercept+methotrexate (ETA+MTX) combination therapy versus step-up MTX monotherapy with ETA added refractory disease. A multi-centre, double-blind, randomized active polyarticular JIA patients treated either ETA+MTX (n = 35) or placebo+MTX 33) for up 24...
Objective. Evaluate growth in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated tocilizumab (TCZ) for up to 2 years a phase III trial. Methods. Patients pcJIA lasting at least 6 months and inadequate response methotrexate received open-label TCZ intravenously every 4 weeks (randomly assigned 8 or 10 mg/kg if they weighed < 30 kg; ≥ kg) 16 weeks. JIA American College of Rheumatology Week were randomly placebo 24 weeks, an extension through 104. Mean ± SD...
Background: Tofacitinib is an oral JAK inhibitor that being investigated for JIA. Objectives: To assess tofacitinib efficacy and safety in JIA patients (pts). Methods: This was a Phase 3, randomised, double-blind (DB), placebo (PBO)-controlled withdrawal study pts aged 2−<18 years with polyarticular course (pcJIA), PsA or ERA ( NCT02592434 ). In the 18-week open-label Part 1, received weight-based doses (5 mg BID lower). Pts ≥JIA ACR30 response at Week (W)18 were randomised 1:1 DB 2...
Introduction: Systemic juvenile arthritis -a rare chronic disease.Registerit's an important tool to monitor the effectiveness and safety of GIBP.Objectives: Our aim was study features drug therapy children with systemic idiopathic (sJIA) Methods: We conducted a retrospective data analysis included in Register sJIA cases, for period from 2002 2015 Results: The indicators 384 are studied.Prior diagnosis verification, all patients were prescribed intake antipyretic agents, 98%...
Background: Enthesitis-related arthritis (ERA) and juvenile psoriatic (JPsA) are two ILAR categories of idiopathic (JIA) represent paediatric correlates axial spondyloarthritis (axSpA) adult (PsA), respectively. 1,2 Secukinumab (SEC) has demonstrated efficacy safety in patients (pts) with PsA, ankylosing spondylitis non-radiographic axSpA. 3-5 Objectives: Evaluate SEC using a flare prevention design pts active ERA JPsA. Methods: This 2-yr study consisted an open-label (OL) s.c. (75/150 mg...
Background/Purpose: The phase 3 CHERISH trial demonstrated the efficacy of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). This analysis investigated progression radiographic joint damage pcJIA treated TCZ for up to 104 weeks CHERISH. Methods: Patients 2 17 years old ≥6 months' active whom methotrexate failed received open-label (OL) according body weight (BW) (BW ≥30 kg, 8 mg/kg [n = 119]; BW...
<h3>Background</h3> Over the past few decades, biologic therapy has significantly improved prognosis in children with JIA. The issue of optimal and personalised biologics prescription problem switching between drugs are relevant questions modern paediatric rheumatology. <h3>Objectives</h3> aim our retrospective observation was to describe trends first subsequent lines for treatment non-systemic <h3>Methods</h3> We recruited 252 patients JIA, who received medical at Department Paediatric...
Study Objective: to present literature review of clinical parameters and course psoriatic arthritis (PsA) in children, results PsA patients examination University Clinical Children Hospital I.M. Sechenov First Moscow State Medical University. Design: open prospective study. Materials Methods. We analysed medical records 83 children with aged 3 17 years who were examined managed 1989 – 2019. Results. Confirmed was diagnosed 59 (71%) suspected — 24 (29%) children; 44 (53%) got ill before they...
Systemic-onset juvenile arthritis (sJIA) is an acute and severe disease characterized by systemic inflammation, extra-articular manifestations. Until now, sJIA considered to be a diagnosis of “exception” requiring careful differential coupled with number other diseases. The purpose this research was evaluate the demographic features sJIA, analyze clinical laboratory data, patients’ compliance diagnostic criteria according International League Associations for Rheumatology's (ILAR)...
Objective. To estimate the immunization coverage and vaccination rate of children (0-17 years age inclusive) with juvenile idiopathic arthritis (JIA) for each individual infection according to regional calendar in Moscow. Patients Methods. An observational analytic cohort study including 753 patients JIA healthy control living Moscow was conducted. Results. have lower than without autoimmune disease; they are also less immunized compared controls, but even rates do not meet targets....
Rheumatoid uveitis is a serious problem in rheumatology and ophthalmology due to the peculiarities of disease – an undistinguished beginning, chronic course high incidence disabling complications. The article analyzes various data on development nature children with juvenile idiopathic arthritis. authors describe analysis results studies this disease. They consider features treatment rheumatoid using genetically engineered biological drugs.
Rationale. Children with rheumatic diseases receiving immunosuppressants and/or genetically engineered biopharmaceutical drugs (GEBDs) glucocorticosteroids (GCs) are at high risk of developing severe long-term symptoms novel coronavirus infection. The possibilities pre-exposure prophylaxis COVID-19 in this patient population significantly limited due to the risks insufficient immunogenicity vaccine presence secondary immunodeficiency developed under conditions immunosuppressive therapy and...
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease of children and adolescents with primary joints involvement various manifestations. Uveitis extra-articular signs characterized by eye inflammation. Standard antirheumatic drugs in combination local therapy are effective 60%. When these ineffective, genetically engineered used JIA rheumatoid uveitis.
The paper presents the results of an open-label nonrandomized prospective trial, purpose which was to evaluate efficiency and safety etanercept (ETC) treatment for different forms variants active juvenile idiopathic arthritis (JIA) in real clinical practice. trial included 24 patients with JIA. ETC proved be effective most a long disease history high laboratory activity who were refractory conventional antirheumatic therapy. therapy articular form showed 100% improvement at least ACRpedi30...
Introduction: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome is a non Mendelian autoinflammatory disorder until now considered to be specifically limited paediatric age.However there recently mounting evidence that children older than 5 years adults may present with the typical picture of PFAPA syndrome.Objectives: We report case 17,5 old girl presenting recurrent episodes fever starting at age 16.Methods: A was referred our department due lasting...
<h3>Background</h3> Remission is the major goal of treatment juvenile idiopathic arthritis(JIA). Advances in options allowed achievement remission to come into reach. Timing for initiating intensive a treat target approach early reach still debate. <h3>Objectives</h3> Multi-centre, double-blind, randomised study polyarticular JIA patients (pts) receiving either Etanercept+Methotrexate (cohort 1) or Placebo +Methotrexate 2) 24 weeks followed by week open label phase. Escape open-label ETN and...
Introduction. Juvenile psoriatic arthritis is a chronic inflammatory disease accounting for 3-10% of all juvenile arthritis. Genetically engineered biological medications, particularly Etanercept, proved to be effective and safe in the adult patients with arthritis; however, there are only few studies on use Etanercept children Objective. To evaluate effectiveness safety Children characteristics research methods . This open, single-center, prospective, observational clinical study...
Objective. To evaluate the frequency, nature, and structure of therapy for uveitis associated with juvenile idiopathic arthritis (JIA) using data from Moscow city register children rheumatic diseases. Patients methods. We analyzed 117 patients JIA aged between 3 17 years residing in Moscow. Results. JIA-associated was diagnosed 11% JIA. It more common females than males (13.1% vs 7.3% respectively). More half (53.8%) had oligoarticular JIA, whereas 34.2% polyarticular RF-seronegative The...